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 Thank you for the opportunity to testify today regarding one of the most urgent 
problems facing humanity – the global AIDS pandemic.  The decisions that the Congress 
and Administration make regarding the pandemic will determine the life or death of 
millions of people in the next few years, and will affect America’s security and standing 
in the world for decades to come.  To date, the United States and other donor countries 
have under-financed AIDS control in poor countries.  This has allowed the pandemic to 
run rampant.  Millions of poor people are needlessly dying every year when their lives 
could be extended by appropriate medical care at modest cost and enormous benefit to 
the United States.       
      
Last month, I visited some of the dying fields of Africa.  I stood in Queen 
Elizabeth Hospital in Blantyre, Malawi where 70 percent of the medical admissions are 
AIDS-related.  Hundreds of patients are crowded into the wards to die, two or three to a 
bed, with patients also lying on the floor under the beds.  Hospital services are collapsing 
under the weight of the epidemic. There are no life-saving drugs given to these people 
because neither the dying patients nor the Government of Malawi can afford the 
medications.   
 
Yet across the hall, an outpatient service successfully treats the small fraction of 
HIV-infected people who can afford one dollar per day.  Hundreds of people are 
successfully on antiretroviral therapy.  The problem in this hospital is not infrastructure, 
doctors, testing equipment, adherence by patients, the ability to tell time – it is simply the 
shortage of $1 per day per patient that would supply life-saving drugs.  Even when one 
adds in the testing and counseling costs in addition to the direct costs of drugs, it is very 
likely that total spending would remain well under $3 per person per day. 
 
While the stain of U.S. neglect during the first 20 years of the pandemic can never 
be washed away, it is not too late to act, for our direct security needs as well as our moral 
purpose as a great nation.  The most important step is for the U.S. Government  to get 
organized to help lead the global war against AIDS.  Currently, the Government lacks: 
clear organizational lines of responsibility (with responsibilities divided among several 
Departments and agencies without any clear leadership); a long-term strategy for a 
scaled-up war against AIDS; and a multi-year budget strategy commensurate with global 
needs (and even lacks a single serious study of the budgetary outlays that will be 
required).  The Administration is moving reactively, not proactively.  It is picking levels 
of budgetary support (such as $200 million in FY03 for the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria) out of the air, not out of a strategy. 
 
In addition to better organization, the United States should increase its spending 
on AIDS control by contributing at least $2.5 billion in FY03 to control of AIDS in poor 
countries, of which at least $2 billion should go the Global Fund, for the reasons 
described below.  Our contribution of $2.5 billion to AIDS control should be matched by 
at least $5 billion from Europe and Japan, for a total outlay of $7.5 billion for HIV/AIDS 
control.  The Global Fund should disburse at least $6 billion for AIDS, tuberculosis, and 
malaria in FY03. 
 
The Global Fund has $700 million available for disbursements in 2002, of which 
the U.S. share is $250 million.  The Congress and the Administration should agree to a 
supplemental appropriation of at least $750 million for FY02, to raise the U.S. 
contribution this year to $1 billion.  This in turn should be matched by at least $2 billion 
from Europe and Japan, for a total of $3 billion. Without this supplemental appropriation, 
the Fund will either run out of money during the year, or will drastically ration the size of 
programs that it approves, to the serious detriment of disease control efforts. 
 
 
Scale of Financial Assistance for HIV/AIDS Control in Poor Countries 
 
 Table 1 breaks down the financing of AIDS control in recent years, and estimates 
the needs for U.S. contributions for AIDS and for total disease control efforts in poor 
countries in the coming years.   
   
 In the second half of the 1990s, America spent around $10 billion dollars per year 
battling the AIDS epidemic at home, but only around $55 million per year in helping 
Sub-Saharan Africa to battle the epidemic.  For all developing countries, spending on 
AIDS was around $120 million per year.  It is worth recalling that the U.S. has about 1 
million HIV-infected individuals, while the developing world has 38 million infected 
individuals.  Treatment costs, I will note below, are of course much lower in the poor 
countries, but the combination of prevention and treatment costs will still require vastly 
higher donor assistance to meet the needs of the tens of millions of individuals already 
infected and the hundreds of millions that are at risk of infection. 
 
U.S. international assistance to fight AIDS has recently begun to increase, to 
around $690 million in FY02 (not including around $188 million in NIH research 
funding), with perhaps two-thirds of that aimed at Africa (depending, for example, on 
allocations from the new Global Fund to Fight AIDS, TB, and Malaria).  The FY03 
budget request again increases the total international spending on HIV/AIDS to around 
$895 million (not including $222 in NIH research funding), with $200 million requested 
for the Global Fund.  While these recent spending increases are certainly in the right 
direction, U.S. assistance is still woefully short of any realistic sum needed to help the 
poorest countries, especially in Sub-Saharan Africa, fight the AIDS pandemic.   
 
Secretary General Kofi Annan has called for $7 to $10 billion per year for the 
control of AIDS in low-income countries, an estimate that has been supported by several 
expert studies, published in the world’s leading journals, such as Science Magazine 
(Schwartlander, et. al., 2000) and elsewhere.  Looking out a few years, the worldwide 
need for donor assistance to control AIDS will probably be at the high end, perhaps 
reaching $10-15 billion depending on the course of the epidemic, the evolution of 
treatment costs, and ability of the low-income countries to scale up AIDS control efforts.   
 
In the past two years, I chaired the WHO Commission on Macroeconomics and 
Health, which was charged in part with determining donor financing needs to address the 
interlocking pandemics of AIDS, malaria, tuberculosis, and other killer diseases.  Our 
study, released in December 2001, determined that Sub-Saharan Africa would need total 
donor assistance for health of around $18 billion per year as of 2007, of which more than 
half would be devoted to the control of AIDS, with the rest directed at other killer 
diseases such as tuberculosis, malaria, vaccine-preventable diseases, respiratory 
infections, and diarrheal diseases.  Since other regions would also need donor assistance 
to fight AIDS, the worldwide need for donor assistance to fight AIDS could reach $10-15 
billion per year by 2007. 
 
Since the U.S. represents around 40 percent of the GNP of the donor world ($10 
trillion out of $25 trillion in total donor GNP), the U.S. share of the total health assistance 
will need to be at least one quarter of the total, if not more.  This means that U.S. 
spending on AIDS in Africa will require at least $2 billion per year, and total U.S. foreign 
assistance for AIDS should reach at least $2.5 to $3 billion per year worldwide in FY03.  
According to the Report of the Commission, total worldwide donor spending on all types 
of health programs should be approximately $27 billion per year by 2007, so that total 
U.S. health assistance would be in the range of $7 - $8 billion per year, roughly five to 
six times the current level. 
 
These numbers may seem large, Senators, but the amount of suffering and global 
risk posed by the pandemic diseases is far greater.  The Commission findings suggest that 
if the U.S. invests on the order of $7 – 8 billion per year as part of a global program of 
around $27 billion per year as of FY07, around 8 million deaths will be averted each year 
by the end of the decade.  We can save 25,000 people every day from deaths due to 
AIDS, malaria, tuberculosis, and other killers if we put our minds, and a modest part of 
our incomes, to it.  Note that $7 to 8 billion per year for global health needs would 
represent far less than one half of one percent of our national budget, and less than one 
penny out of every 10 dollars of our income.        
         
 The United States, while the second largest donor in absolute terms (after Japan), 
has become the smallest donor in the world when aid is measured as a share of income!  
(Chart 1).  We are now spending only 0.1 percent of GNP on all forms of official 
development assistance, compared with an average of more than 0.3 percent of GNP in 
Europe.  The oft-repeated excuse that “aid does not work” is a cruel abnegation of U.S. 
responsibility.  We must stop talking about “aid” in generic terms, and start discussing 
targeted financial support for specific health interventions – such as prevention and 
treatment of AIDS, increased coverage of immunizations, wider dissemination of anti-
malaria bednets, and the like.  History demons trates that such targeted interventions have 
a high success rate.  From the expanded program on immunization (EPI); to the 
campaigns against smallpox, polio, African river blindness, and trauchoma; to the spread 
of oral rehydration therapy; directly observed therapy short-course (DOTS) for 
tuberculosis, and insecticide- impregnated bednets, foreign assistance for health has 
worked well.  Unfortunately, the level of aid has always been tragically meager compared 
with the level of need. 
 
 
Donor support for Ant i-Retroviral Therapy in Poor Countries 
 
 Life-saving antiretroviral combination therapies have been available since the 
mid-1990s.  Yet given the low levels of donor assistance, the stunning fact is that not one 
person in the developing world – out of the more than 60 million who have been infected 
by the HIV virus since 1981 – has received such drugs through official donor support 
from the U.S. or any other country or multilateral institution. Let me repeat that, 
Senators.  Not one person in the developing world has yet received donor-supported 
antiretroviral therapy!  The U.S. and other leading donors have so far turned their backs 
on millions of dying people.  This dreadful fact is supposed to change, finally this year, 
when the Global Fund and USAID both begin to support the introduction of antiretroviral 
therapy.  Yet the donor sums so far committed in 2002 will permit only a very small 
scaling up of treatment relative to the enormous needs.    
 
For many years it was casually supposed that antiretroviral treatment was too 
expensive for low-income countries.  Drug regimens cost $10,000 or more per year in the 
United States.  But it has come to be understood that the prices of antiretrovirals in the 
U.S. are vastly higher than the actual production costs, which are probably on the order of 
$300 - $750 dollars per regimen per year, depending on the precise combination of 
medicines.  The high margin of the price over marginal production cost reflects the 
returns on research and development, a margin that is properly protected by patent rights.  
Yet, the lower production costs make it possible to provide the low-income world with 
the drugs at the actual marginal cost of production, close to $1 per day for the least 
expensive combinations.  The leading pharmaceutical companies, and high-quality 
generic producers that have access to the African market (which has little patent coverage 
for most of the relevant drugs) have shown their readiness to provide drugs at the much 
reduced prices.  Still, the impoverished countries in Africa require donor assistance even 
to cover the costs of $1 per day for the drugs (and perhaps another $1 per day on average 
for the accompanying testing and medical care).      
 
 A high-end estimate is that anti-retroviral treatment will require around $1,000 
per patient per year in low-income settings, including the costs of drugs, testing, and 
medical care.  This can probably be reduced to around $500 per patient per year with 
further reductions in drug prices, and optimized regimens regarding testing and medical 
care.  Of the 25 million Africans currently infected with HIV, perhaps 4 to 5 million 
would qualify for highly active antiretroviral therapy on clinical grounds.  Of these, it is 
estimated that perhaps 25,000 – 50,000 are currently receiving the medicines, while the 
rest are dying.  Even those receiving the medicines are often on sub-optimal regimens, 
with interruptions of drug availability, inadequate drug combinations, and poor 
monitoring. 
 
 UNAIDS, WHO, and other expert groups that have looked closely at this believe 
that 5 million people in low-income settings, mainly in Africa, could be on successful 
antiretroviral therapy within 5 years.  Indeed, the numbers could be even higher is scaling 
up is given adequate support.  That would suggest a total cost of around $5 billion per 
year for antiretroviral treatment by FY07, plus the costs of prevention programs and 
treatment for opportunistic infections, thereby arriving at the cost estimate of $9 – 12 
billion of donor support by FY07.    
 
 
The Global AIDS Pandemic and U.S. Security 
 
 Let me briefly address the highly adverse foreign policy implications of the AIDS 
epidemic for the United States, and then discuss the importance of scaling up treatment, 
including anti-retroviral therapy, to control the epidemic. 
 
AIDS is destroying the prospects for African economic development and democracy 
 
The greatest hope for democracy and economic progress in Africa remain our 
friends such as South Africa, Nigeria, Botswana, Ghana, Mozambique, Malawi, and 
Tanzania.  These nations, among many others in the region, are being ravaged by AIDS.  
Foreign investment has been seriously impeded as investors avoid countries where a 
significant proportion of the labor force is likely to be HIV-infected.  It is not poor 
villagers alone who are dying: an entire educated and professional class is disappearing.  
The labor force, including the most highly productive age groups, is being wiped out.  
Sub-Saharan Africa now has 25 million HIV-infected individuals, roughly 9 percent of 
the adult population between the ages 15 and 44.  More than two million Africans are 
dying of AIDS each year.  In Southern and Eastern Africa, the prevalence is well above 
10 percent, and in hard hit countries, 25 percent or more.  AIDS has become a dire and 
fundamental impediment to economic progress in Africa and leaves an even more 
troubling legacy: tens of millions of orphaned children.   
 
AIDS is creating a demographic catastrophe, with profound security risks 
 
AIDS has already left behind more than 12 million orphans, and epidemiological 
estimates suggest that the number could rise to 40 million by the end of the decade unless 
the pandemic is staunched.  As America lets millions of African die for want of $1 per 
day in medicines, millions more children are left orphaned.  Common sense and repeated 
studies have shown that these children are at great risk of hunger, neglect, withdrawal 
from schooling, crime and violence.   
 
AIDS is creating a breeding ground for terrorism 
 
Disease is repeatedly found to be one the most powerful predictors of state 
collapse and internal violence.  The CIA Task Force on State Failure identifies high 
infant mortality rates as one of the three most powerful predictors of subsequent state 
failure (in addition to lack of democracy and lack of open economy).  Furthermore, AIDS 
is decimating adult populations and increasing the percentage of populations which are 
aged between 15 and 24.  Research has determined that such demographic shifts are a 
major predictor for the outbreak of conflict.    
 
AIDS is fomenting a social and political backlash against the United States 
 
Throughout Africa and the developing world, people believe that they have been 
left to die by America.  They are aware that life-saving drugs exist to save them, but that 
those drugs are not being made available.  Conspiracy theories abound in Africa that 
AIDS is a deliberate policy of genocide by the United States, or an accident of the CIA 
gone awry.  These desperate flights of fancy aside, our actions to date point to one 
conclusion:  America judges African lives to be worth less than $1 or $2 per day.    
   
AIDS is threatening China and India and other parts of the world 
 
What has come to Africa will soon be true in the populous centers of Asia, 
including India and China, where the epidemic is still in its early stages.  The 
destabilization that could arise from full- fledged epidemics in those countries is 
harrowing.  We must not ignore the central truth about epidemics:  they are far less costly 
to control at an early stage.   
 
AIDS is threatening U.S. public health 
 
AIDS originated in Africa, probably West Africa, sometime around 1930 
according to the best current estimates.  It went undetected for decades, in part because of 
the remarkably poor state of public health surveillance in Africa, and was only identified 
as a new disease in 1981 after it had spread to the United States.  In this sense, AIDS is 
precisely the kind of threat of cross-border transmission of infectious diseases that public 
health officials have warned us about for decades.  Our neglect of burgeoning infections 
abroad – whether from AIDS, or tuberculosis, or other new and rapidly evolving viral and 
bacterial conditions – poses stark risks to American public health.  The day has already 
arrived when any one of us could, during a flight or in a theater, be infected with multi-
drug resistant tuberculosis, the treatment of which involves two years of chemotherapy.  
AIDS is also evolving rapidly, and there are reasons to suspect that some viral subtypes 
may be more transmissible and virulent than others.  New forms of the disease in Africa 
or elsewhere, especially if uncontrolled, will readily jump to the United States with dire 
consequences.  Thus, we must act decisively not only because it will save lives abroad; it 
will save lives here at home as well.     
 
 
Designing a Control Strategy that Can Meet the Challenge of a Global Pandemic 
 
AIDS requires a comprehensive strategy, including both prevention and treatment  
 
The most pernicious myth of donor policy has been that prevention alone, without 
treatment, will control the epidemic.  This view is brutally shortsighted and 
fundamentally flawed.  Both prevention and treatment are necessary.  In the Report of the 
Commission on Macroeconomics and Health, we concluded that total spending on AIDS 
should fall into three roughly equal categories: prevention programs; treatment of 
opportunistic infections; and antiretroviral therapy.   
 
Anti-retroviral therapy is necessary for two basic reasons.  First, we cannot afford 
to allow millions of working-age Africans -- mothers and fathers and core members of 
the labor force -- to die for lack of $1- 2 per day in medicines and treatment costs, given 
the enormous resulting losses in economic development, the millions of orphans that 
would be left behind, and the resulting threats of violence, political destabilization, and 
social upheaval.  It is just dreadful economic miscalculation to believe that it is “cost 
effective” to stand by and allow a generation to die for lack of $500 - $1000 per patient 
per year for medicines and ancillary care.   
 
Second, treatment is vital for successful prevention.  In the United States, the 
Centers for Disease Control terms antiretroviral treatment a form of “secondary 
prevention.” The availability of treatment encourages people to get tested for HIV 
infection, and then to receive counseling if they are infected.  Yet in Africa, where testing 
is not now followed by treatment, individuals rarely seek testing and counseling, and it is 
estimated that fewer than 5 percent of HIV-infected individuals actually know their 
status.  Without counseling and testing, one of the key methods of limiting transmission 
is lost.     
 
The benefits of treatment for prevention go well beyond encouraging counseling 
and testing.  Stigma is reduced when the disease is known to be treatable, and the disease 
can be addressed in much more direct and sensible manner.  Irrational and often highly 
destructive social interpretations of the disease (e.g. that it is a form of witchcraft, or a 
CIA form of bioterrorism, or that it can be cured by having sex with a virgin) are 
diminished as soon as successful medical interventions are demonstrated.  Politicians stop 
hiding from the epidemic when they can offer hope to their populations.  Medical staffs, 
currently unable to save their dying patients for want of medicines, are re-energized to 
fight the epidemic.   
 
Treatment is feasible at a greatly enlarged scale 
 
Physicians experienced in Africa know that treatment can be successfully scaled 
up dramatically.  Many doctors in Africa and other resource-poor settings are already 
successfully treating patients, but only the small proportion who are able to purchase the 
drugs out of pocket.  With concerted financial support, training to African medical 
personnel could be expanded dramatically; testing facilities could be expanded or 
created; and new protocols could be elaborated to ensure a reliable flow of drugs and 
high patient adherence to drug regimens.  WHO and UNAIDS estimate that at least 5 
million patients in low-income settings could be on anti-retroviral therapy by the end of 
2006.   
 
The Global Fund is the best single investment for the United States in AIDS control 
 
The Global Fund to Fight AIDS, Tuberculosis, and Malaria is an important new 
weapon in the fight against AIDS.  The Fund was formally launched in January 2002, and 
will receive the first round of proposals by March 10, 2002.  Initial funding is likely to 
begin by late April.   
 
The Global Fund has several key strengths.   
 
(1) The Fund will be the key source of multilateral grant financing for AIDS control in 
low-income countries, especially since the World Bank is still hamstrung in making loans 
rather than grants for AIDS control efforts in low-income countries; 
 
(2) The Fund effectively pools donor resources, so that countries can create a 
comprehensive strategy and apply to one single source of financing, rather than to twenty 
or more distinctive and often contradictory assistance programs supported by individual 
bilateral donors; 
 
(3) The Fund leverages U.S. funding by encouraging donor support from Europe, Japan, 
and other high- income countries.  The initial U.S. contribution of $300 million combined 
in FY01 and FY02 has now been matched by at least $1.5 billion from other donors.  
While the total sums are still far too low, the leveraging of U.S. aid is clear;   
 
(4) The Fund offers Congress and the international community a transparent mechanism 
for monitoring the flow of funding proposals and funding decisions, thereby helping to 
ensure that donor funds are disbursed in a sensible and evidence-based manner.  One of 
the strongest features of the Global Fund is that proposals will be vetted by an 
independent expert review committee;    
 
(5) The Fund is already spurring initiative at the grass roots (including local non-
governmental organizations), as well as increased collaboration between governments 
and civil society; 
 
(6) The Fund will enable selectivity in the choice of programs and countries that will be 
funded, so that funds can be held back from corrupt governments and inappropriate 
programs; 
 
(7) The Fund will enable improved monitoring and auditing of the actual use of donor 
funds. 
 
(8) Programs supported by the Fund can and should include financing for operational and 
clinical research linked to the provision of health services.  The Fund can be an important 
vehicle for financing the research necessary to optimize treatment protocols.   
 
 
Research Efforts Should Be Intensified  
 
The U.S., through the National Institutes of Health, is already the world’s leader 
in basic research in AIDS.  This leadership should be maintained and enhanced, with 
increased research contributions from other donors as well.  Recent advances in vaccine 
research suggest that an effective vaccine may be available within a decade, if not sooner.  
There will need to be considerable coordination across countries in the basic research, 
product development, and clinical testing, to speed the process.  The International AIDS 
Vaccine Initiative, among others, has already made important strides in this area, and 
work by IAVI and others should be supported by the U.S. Government.   
 
 In addition to basic research on the immunology and pathophysiology of AIDS, 
and applied research on vaccines and therapeutics, the U.S. should actively support 
clinical and operational research into treatment protocols, as well as epidemiological and 
behavioral research related to the transmission of the disease on the population level.  
The Fogarty Institute at the National Institutions of Health can play a key role in 
strengthening the capacity of poor countries to carry out clinical and operational research, 
in programs such as the awards for International Clinical, Operational, and Health 
Services Research (ICOHRTA).  The Centers for Disease Control can play a key role in 
helping countries with the epidemiological and behavioral research, as well as 
surveillance studies.        
 
 
Immediate Steps  
 
Budgetary outlays of $2.5 billion FY03 
 
The Congress and Administration should support a U.S. contribution to AIDS 
control of at least $2.5 billion in FY03, of which the Global Fund should receive at least 
$2 billion, compared with the Administration’s request of $200 million.  The $500 
million minimum of additional funding should support programs of USAID, NIH, and 
CDC. 
 
Supplemental budget in FY02 
 
Congress and the Administration should be prepared to make a supplemental 
appropriation for the Fund during FY02 of $750 million, raising the FY02 U.S. 
contribution to $1 billion. 
 
Bi-partisan Congressional Mission to Africa during this Spring 
 
 Given the urgency of the global AIDS pandemic, and the role that the U.S. must 
play to overcome it, it is critical for Congressional leaders and staff to understand the 
crisis on a first-hand basis.  Much of what is reported, especially the alleged obstacles of 
effective treatment in the African context, does not reflect on-the-ground reality.  
Moreover, the sheer scale of the crisis is difficult to fathom without a first-hand view.    
 
 For this reason, I strongly urge that the Congressional leadership appoint a bi-
partisan mission to travel to Africa and to report back to the Congress this Spring.  The 
claims and counter-claims can then be evaluated directly, and the shocking enormity of 
the crisis will better be brought to the American people through their Representatives in 





The United States has missed an enormous opportunity during the past two 
decades to establish global leadership in quelling the AIDS epidemic.  It’s been an 
opportunity to not only save lives and make a contribution to the global economy; it’s 
been an opportunity to promote enormous good will towards our nation, to shore up 
democracy and economic growth, and to lessen the threats posed by destabilized states.   
 
I come today bearing one message: today is not too late to act.  While millions 
have died and instability has grown, we can still avert the worst.  Senators, in our 
lifetimes our children and grandchildren will ask us what our country did during the 
worst epidemic to strike humankind.  With your leadership, I hope that we shall be able 
to offer a response that makes us all proud to be Americans.   
Table 1.  Estimated Budgetary Outlays and Needs for AIDS and All Disease Control 
 FY95-
99 
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